Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.
Lianghua FangQing XuJun QianJin-Yong ZhouPublished in: OncoTargets and therapy (2021)
Aberrant factors associated with fibrinolysis and thrombosis are found in many cancer patients, which can promote metastasis and are associated with poor prognosis. The relationship between tumor-associated fibrinolysis and thrombosis is poorly understood in pancreatic cancer. This review provides a brief highlight of existing studies that the fibrinolysis and coagulation systems were activated in pancreatic cancer patients, along with aberrant high concentrations of tissue plasminogen activator (t-PA), urine plasminogen activator (u-PA), D-dimer, fibrinogen, or platelets. These factors cooperate with each other, propelling tumor cell shedding, localization, adhesion to distant metastasis. The relationship between thrombosis or fibrinolysis and cancer immune escape is also investigated. In addition, the potential prevention and therapy strategies of pancreatic cancer targeting factors in fibrinolysis and coagulation systems are also been discussed, in which we highlight two effective agents aspirin and low-molecular weight heparin (LMWH). Summarily, this review provides new directions for the research and treatment of pancreatic cancer.
Keyphrases
- poor prognosis
- pulmonary embolism
- long non coding rna
- cell therapy
- low dose
- stem cells
- venous thromboembolism
- escherichia coli
- squamous cell carcinoma
- cancer therapy
- coronary artery disease
- climate change
- risk assessment
- pseudomonas aeruginosa
- squamous cell
- mesenchymal stem cells
- bone marrow
- human health
- mass spectrometry
- high resolution
- cell adhesion
- candida albicans
- lymph node metastasis
- anti inflammatory drugs
- cell migration